Ser16

Site Information
RSAIRRAstIEMPQQ SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 448114
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	immunoassay ( 5 ) , immunoprecipitation ( 6 ) , mass spectrometry ( 7 , 8 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 ) , mutation of modification site ( 4 , 35 , 57 ) , phospho-antibody ( 1 , 2 , 3 , 5 , 6 , 9 , 10 , 55 , 56 , 57 ) , western blotting ( 1 , 2 , 3 , 6 , 9 , 10 , 55 , 57 )
Disease tissue studied:	atrial fibrillation ( 10 , 43 , 46 , 47 ) , breast cancer ( 40 ) , HER2 positive breast cancer ( 7 ) , luminal A breast cancer ( 7 ) , luminal B breast cancer ( 7 ) , breast cancer, triple negative ( 7 ) , lung cancer ( 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 31 , 34 ) , non-small cell lung cancer ( 15 , 16 , 17 , 19 , 20 , 21 , 31 , 34 ) , non-small cell lung cancer, surrounding tissue ( 32 ) , non-small cell lung adenocarcinoma ( 15 , 16 , 17 , 18 , 19 , 20 , 21 ) , non-small cell large cell lung carcinoma ( 16 , 19 ) , non-small cell squamous cell lung carcinoma ( 18 ) , small-cell lung cancer ( 13 , 14 ) , lung cancer, surrounding tissue ( 30 ) , neuroblastoma ( 48 , 49 ) , pancreatic ductal adenocarcinoma ( 12 ) , melanoma skin cancer ( 8 , 29 , 33 ) , ventricular tachycardia ( 10 , 25 )
Relevant cell line - cell type - tissue:	'heart, papillary muscle' ( 41 , 42 , 56 ) , 'muscle, skeletal' ( 26 , 28 ) , 'pancreatic, ductal'-pancreas ( 12 ) , 293 (epithelial) [AT1 (human), transfection] ( 27 ) , 293 (epithelial) ( 3 , 4 , 35 ) , A549 (pulmonary) ( 15 ) , ARVM (myocyte) ( 6 ) , breast ( 7 , 40 ) , Cal-12T (pulmonary) ( 21 ) , Calu-3 (pulmonary) ( 17 ) , DMS153 (pulmonary) ( 20 ) , DMS53 (pulmonary) ( 14 ) , DMS79 (pulmonary) ( 13 ) , HCC15 (pulmonary) ( 18 ) , HCC44 (pulmonary) ( 21 ) , HCC78 (pulmonary) ( 19 ) , HCC827 (pulmonary) ( 17 ) , heart ( 1 , 2 , 3 , 10 , 25 , 43 , 44 , 45 , 46 , 47 , 50 , 51 , 57 ) , HEK293T (epithelial) ( 57 ) , LOU-NH91 (squamous) ( 18 ) , lung ( 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 30 , 31 , 32 , 34 ) , myocyte-heart ( 9 , 55 , 56 ) , NCI-H128 (pulmonary) ( 13 ) , NCI-H1299 (pulmonary) ( 16 ) , NCI-H1355 (pulmonary) ( 15 ) , NCI-H1417 (pulmonary) ( 13 ) , NCI-H1437 (pulmonary) ( 20 , 21 ) , NCI-H1650 (pulmonary) ( 17 ) , NCI-H1666 (pulmonary) ( 21 ) , NCI-H1703 (squamous) ( 18 ) , NCI-H1734 (pulmonary) ( 16 ) , NCI-H1781 (pulmonary) ( 19 ) , NCI-H1792 (pulmonary) ( 15 ) , NCI-H1944 (pulmonary) ( 16 ) , NCI-H1975 (pulmonary) ( 17 ) , NCI-H2073 (pulmonary) ( 18 , 20 ) , NCI-H209 (pulmonary) ( 13 , 20 ) , NCI-H2106 (pulmonary) ( 17 ) , NCI-H2228 (pulmonary) ( 19 ) , NCI-H23 (pulmonary) ( 15 ) , NCI-H2342 (pulmonary) ( 18 ) , NCI-H2405 (pulmonary) ( 21 ) , NCI-H3122 (pulmonary) ( 19 ) , NCI-H358 (pulmonary) ( 16 ) , NCI-H441 (pulmonary) ( 15 ) , NCI-H446 (pulmonary) ( 14 ) , NCI-H460 (pulmonary) ( 16 ) , NCI-H524 (pulmonary) ( 13 ) , NCI-H526 (pulmonary) ( 14 ) , NCI-H661 (pulmonary) ( 19 ) , NCI-H69 (pulmonary) ( 14 ) , NCI-H82 (pulmonary) ( 14 ) , NCI-H838 (pulmonary) ( 20 ) , skin ( 29 , 33 ) , SMS-KCN (neural crest) ( 48 , 49 ) , WM239A (melanocyte) ( 8 )

Upstream Regulation
Regulatory protein:	PPP1R1A (human) ( 54 ) , YSK1 (human) ( 2 )
Putative in vivo kinases:	PKACA (human) ( 2 , 3 , 5 )
Kinases, in vitro:	PKACA (human) ( 3 , 58 )
Putative upstream phosphatases:	PPP2CA (human) ( 9 )
Treatments:	5-HT ( 10 ) , AACOCF3 ( 55 ) , cAMP_analog ( 5 ) , colforsin ( 10 ) , histamine ( 1 ) , hypothermia ( 1 ) , isoproterenol ( 2 , 3 , 5 , 9 ) , norepinephrine ( 10 ) , racepinefrine ( 10 ) , SNAC ( 5 ) , zinterol ( 55 )

Downstream Regulation
Effects of modification on PLB:	activity, induced ( 57 ) , activity, inhibited ( 3 ) , enzymatic activity, induced ( 5 ) , molecular association, regulation ( 3 , 4 , 35 , 58 ) , protein conformation ( 35 )
Inhibit interaction with:	ATP2A1 (human) ( 35 ) , SERCA2 (human) ( 3 , 4 , 58 )

References
1	Hoffmann RJR, et al. (2023) Temperature alters the inotropic, chronotropic and proarrhythmic effects of histamine in atrial muscle preparations from humans and H-receptor overexpressing mice. Naunyn Schmiedebergs Arch Pharmacol 396, 2137-2150 36951998 Curated Info
2	Zhang X, et al. (2022) STK25 inhibits PKA signaling by phosphorylating PRKAR1A. Cell Rep 40, 111203 35977512 Curated Info
3	Vafiadaki E, et al. (2022) Aberrant PLN-R14del Protein Interactions Intensify SERCA2a Inhibition, Driving Impaired Ca Handling and Arrhythmogenesis. Int J Mol Sci 23 35805951 Curated Info
4	Cleary SR, et al. (2022) Inhibitory and Stimulatory Micropeptides Preferentially Bind to Different Conformations of the Cardiac Calcium Pump. J Biol Chem, 102060 35605666 Curated Info
5	Tsutsui K, et al. (2021) cAMP-Dependent Signaling Restores AP Firing in Dormant SA Node Cells via Enhancement of Surface Membrane Currents and Calcium Coupling. Front Physiol 12, 596832 33897445 Curated Info
6	Weeks KL, et al. (2017) β-Adrenergic Stimulation Induces Histone Deacetylase 5 (HDAC5) Nuclear Accumulation in Cardiomyocytes by B55α-PP2A-Mediated Dephosphorylation. J Am Heart Assoc 6 28343149 Curated Info
7	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
8	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
9	Kirchhefer U, et al. (2014) Cardiac Function Is Regulated by B56α-mediated Targeting of Protein Phosphatase 2A (PP2A) to Contractile Relevant Substrates. J Biol Chem 289, 33862-73 25320082 Curated Info
10	Christ T, et al. (2014) Arrhythmias, elicited by catecholamines and serotonin, vanish in human chronic atrial fibrillation. Proc Natl Acad Sci U S A 111, 11193-8 25024212 Curated Info
11	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
12	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
13	Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
14	Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
15	Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
16	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
17	Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
18	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
19	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
20	Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
21	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
22	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
23	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
24	Rikova K (2012) CST Curation Set: 14275; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
25	Li Y (2011) CST Curation Set: 10522; Year: 2011; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
26	Zhao X, et al. (2011) Phosphoproteome analysis of functional mitochondria isolated from resting human muscle reveals extensive phosphorylation of inner membrane protein complexes and enzymes. Mol Cell Proteomics 10, M110.000299 20833797 Curated Info
27	Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304 20686112 Curated Info
28	Højlund K, et al. (2009) In vivo phosphoproteome of human skeletal muscle revealed by phosphopeptide enrichment and HPLC-ESI-MS/MS. J Proteome Res 8, 4954-65 19764811 Curated Info
29	Tucker M (2009) CST Curation Set: 8385; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
30	Rikova K (2009) CST Curation Set: 6634; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
31	Rikova K (2009) CST Curation Set: 6629; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
32	Rikova K (2009) CST Curation Set: 6631; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
33	Tucker M (2009) CST Curation Set: 6418; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
34	Rikova K (2008) CST Curation Set: 5742; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
35	Hou Z, Kelly EM, Robia SL (2008) Phosphomimetic mutations increase phospholamban oligomerization and alter the structure of its regulatory complex. J Biol Chem 283, 28996-9003 18708665 Curated Info
36	Stokes M (2008) CST Curation Set: 5288; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
37	Stokes M (2008) CST Curation Set: 5280; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
38	Stokes M (2008) CST Curation Set: 5281; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
39	Stokes M (2008) CST Curation Set: 5282; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
40	Tucker M (2008) CST Curation Set: 5193; Year: 2008; Biosample/Treatment: tissue, breast/untreated; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
41	Stokes M (2008) CST Curation Set: 5085; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
42	Stokes M (2008) CST Curation Set: 5086; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
43	Stokes M (2008) CST Curation Set: 5095; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
44	Stokes M (2008) CST Curation Set: 5096; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
45	Stokes M (2008) CST Curation Set: 5097; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
46	Stokes M (2008) CST Curation Set: 5098; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
47	Stokes M (2008) CST Curation Set: 5099; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
48	Guo A (2008) CST Curation Set: 5180; Year: 2008; Biosample/Treatment: cell line, SMS-KCN/BDNF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
49	Guo A (2008) CST Curation Set: 5181; Year: 2008; Biosample/Treatment: cell line, SMS-KCN/BDNF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
50	Stokes M (2008) CST Curation Set: 4142; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
51	Stokes M (2008) CST Curation Set: 4066; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
52	Stokes M (2008) CST Curation Set: 3938; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
53	Stokes M (2008) CST Curation Set: 3939; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
54	Rodriguez P, et al. (2007) Phosphorylation of human inhibitor-1 at Ser67 and/or Thr75 attenuates stimulatory effects of protein kinase A signaling in cardiac myocytes. Am J Physiol Heart Circ Physiol 293, H762-9 17416610 Curated Info
55	Ait-Mamar B, et al. (2005) The cytosolic phospholipase A2 pathway, a safeguard of beta2-adrenergic cardiac effects in rat. J Biol Chem 280, 18881-90 15728587 Curated Info
56	Valverde CA, et al. (2005) Frequency-dependent acceleration of relaxation in mammalian heart: a property not relying on phospholamban and SERCA2a phosphorylation. J Physiol 562, 801-13 15528241 Curated Info
57	Hoshijima M, et al. (2002) Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 8, 864-71 12134142 Curated Info
58	Kimura Y, Inui M (2002) Reconstitution of the cytoplasmic interaction between phospholamban and Ca(2+)-ATPase of cardiac sarcoplasmic reticulum. Mol Pharmacol 61, 667-73 11854448 Curated Info